Efficacy and safety of a new, chromatographically purified rhesus (D) immunoglobulin

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 117, Issue 2, 2004, Pages 154-161

  MacKenzie, Ian Z ^a   Bichler, Johann ^b   Mason, Gerald C ^c   Burnett Lunan, C ^d   Stewart, Peter ^e   Al Azzawi, Farook ^f   De Bono, Martin ^g   Watson, Neale ^h   Andresen, Irmgard ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b ZLB Bioplasma AG   (Switzerland)

^c LEEDS GENERAL INFIRMARY   (United Kingdom)

^d Princess Royal Maternity Hospital ^*  (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

^f LEICESTER ROYAL INFIRMARY   (United Kingdom)

^g Halifax General Hospital   (United Kingdom)

^h HILLINGDON HOSPITAL   (United Kingdom)

Author keywords

Anti D; Clinical trial; Rhesus prophylaxis

Indexed keywords

RHESUS D ANTIBODY; RHOPHYLAC;

ADULT; ARTICLE; BLOOD SAMPLING; CHROMATOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNIZATION; LABORATORY; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTICENTER STUDY; PREGNANCY; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN PURIFICATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

EID: 8444230058     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2004.03.009     Document Type: Article

References (21)

1. Pollack W., Gorman J.G., Freda V.J., Ascari W.Q., Allen A.E., Baker W.J. Results of clinical trials of RhoGAM in women. Transfusion. 8:1968;151-153
2. Bowman J.M. The prevention of Rh immunization. Transfus. Med. Rev. 2:1988;129-150
3. Hartwell E.A. Use of Rh immune globulin. ASCP practice parameter. Am. J. Clin. Pathol. 110:1998;281-292
4. Guidance on the use of routine antenatal anti-D prophylaxis for RhD-negative women. Technology Appraisal Guidance No. 41. London, UK: National Institute for Clinical Excellence, May 2002.
5. 2 -globulin antibody preparation: a preliminary report. Transfusion. 4:1964;26-32
6. Bowman J.M. The advantages of intravenous Rh-immune globulin. Clin. Obstet. Gynaecol. 25:1982;341-347
7. Hoppe H.H., Krebs H.J., Mester T., Hennig W. Herstellung von anti-rh-gammaglobulin zur immunisierungs-prophylaxe. Münch Med. Wochenschr. 109:1967;1749-1752
8. Friesen A.D., Bowman J.M., Price H.W. Column ion-exchange preparation and characterization of an Rh immune globulin (WinRho) for intravenous use. J. Appl. Biochem. 3:1981;164-175
9. Stucki M., Moudry R., Kempf C., Omar A., Schlegel A., Lerch P.G. Characterisation of a chromatographically produced anti-D immunoglobulin product. J. Chromatogr. B. 700:1997;241-248
10. Horowitz B., Bonomo R., Prince A.M., Chin S., Brotman B., Shulman R.W. Solvent detergent treated plasma: a virus-inactivated substitute for frozen plasma. Blood. 79:1992;826-831
11. Bichler J., Schöndorfer G., Pabst G., Andresen I. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women. BJOG. 110:2003;39-45
12. Committee for Proprietary Medicinal Products (CPMP). Guidelines to assess efficacy and safety of normal intravenous immunoglobulin products for marketing authorisations. CPMP/BPWP/388/95. London: The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, February 29, 1996.
13. Core SPC, for Human Anti-D Immunoglobulin for Intravenous and/or Intramuscular Use (CPMP/BPWG/574/99). London, The European Agency for the Evaluation of Medical Products, Human Medicines Evaluation Unit, June 29, 2000.
14. Note for Guidance on the Clinical Investigation of Human Anti-D Immunoglobulin for Intravenous and/or Intramuscular Use (CPMP/BPWG/575/99). London, The European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit, June 29, 2000.
15. Britt WJ, Alford CA. Cytomegalovirus. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers, 1996. p. 2493-513.
16. Technical Manual of the American Association of Blood Banks. 12th ed. Bethesda, MD, USA: American Association of Blood Bank, 1996.
17. Duguid J.K.M., Bromilow I.M. What is the true rate of RhD isoimmunization in the UK. Brit. J. Obstet. Gynecol. 105(Suppl.):1998;18-33
18. Lehmann R., Kiefel V. Detection of red cell alloantibodies by gel centrifugation test. A long term evaluation of results. Infus. Ther. Tranfus. Med. 28:2001;V20.2
19. Bowman J.M., Cown B., Lewis M., Pollock J.M. Rh-isoimmunization during pregnancy: antenatal prophylaxis. Can. Med. Assoc. J. 118:1978;623-627
20. Tovey L.A., Taverner J.M. A case for the antenatal administration of anti-D immunoglobulin to primigravidae. Lancet. 1:1981;878-881
21. MacKenzie I.Z., Bowell P., Gregory H., Pratt G., Guest C., Entwistle C.C. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study. Brit. J. Obstet. Gynaecol. 106:1999;492-497